UCB Inkomsten in het verleden

Verleden criteriumcontroles 1/6

De winst van UCB is gedaald met een gemiddeld jaarlijks percentage van -17.4%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 12.9%. De inkomsten zijn groeide met een gemiddeld percentage van 1.4% per jaar. Het rendement op het eigen vermogen UCB bedraagt 2.7% en de nettomarge bedraagt 4.4%.

Belangrijke informatie

-17.4%

Groei van de winst

-17.6%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	7.3%
Inkomstengroei	1.4%
Rendement op eigen vermogen	2.7%
Nettomarge	4.4%
Volgende winstupdate	27 Feb 2025

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe UCB geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

DB:UNC0 Opbrengsten, kosten en inkomsten (EUR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	5,454	240	2,033	1,660
31 Mar 24	5,318	292	1,929	1,645
31 Dec 23	5,182	343	1,824	1,630
30 Jun 23	5,111	332	1,726	1,631
31 Mar 23	5,279	376	1,720	1,651
31 Dec 22	5,447	420	1,714	1,670
30 Jun 22	5,854	887	1,695	1,674
31 Mar 22	5,816	971	1,625	1,652
31 Dec 21	5,777	1,055	1,554	1,629
30 Sep 21	5,647	996	1,506	1,631
30 Jun 21	5,517	936	1,458	1,633
31 Mar 21	5,432	834	1,438	1,601
31 Dec 20	5,347	732	1,417	1,569
30 Jun 20	5,198	743	1,368	1,393
31 Mar 20	5,056	767	1,336	1,333
31 Dec 19	4,913	790	1,303	1,272
30 Jun 19	4,686	652	1,212	1,229
31 Mar 19	4,659	722	1,178	1,195
31 Dec 18	4,632	792	1,144	1,161
30 Jun 18	4,569	872	1,105	1,083
31 Mar 18	4,522	812	1,119	1,070
31 Dec 17	4,474	752	1,132	1,057
30 Sep 17	4,400	708	1,138	1,047
30 Jun 17	4,325	664	1,144	1,036
31 Mar 17	4,236	604	1,133	1,028
31 Dec 16	4,147	543	1,122	1,020
30 Sep 16	4,051	439	1,111	1,022
30 Jun 16	3,955	334	1,099	1,023
31 Mar 16	3,916	299	1,098	1,030
31 Dec 15	3,876	264	1,096	1,037
30 Sep 15	3,773	266	1,069	999
30 Jun 15	3,670	268	1,042	961
31 Mar 15	3,507	192	1,011	945
31 Dec 14	3,344	115	980	928
30 Sep 14	3,206	114	963	905
30 Jun 14	3,067	112	946	881
31 Mar 14	3,100	97	971	884
31 Dec 13	3,133	82	996	886

Kwaliteitswinsten: UNC0 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (4.4%) UNC0 } zijn lager dan vorig jaar (6.5%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van UNC0 is de afgelopen 5 jaar met 17.4% per jaar gedaald.

Versnelling van de groei: De winstgroei UNC0 is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: UNC0 had het afgelopen jaar een negatieve winstgroei ( -27.7% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Pharmaceuticals ( 28.7% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 2.7% ) van UNC0 wordt als laag beschouwd.

UCB Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden